Related Experiment Video

Updated: Jun 23, 2025

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy
05:06

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy

Published on: November 10, 2023

959

Special Issue "Latest Advances in Nanomedicine Strategies for Different Diseases"

Nagavendra Kommineni1, Veera Ganesh Yerra2

  • 1Center for Biomedical Research (CBR) Population Council, The Rockefeller University, New York, NY 10065, USA.

International Journal of Molecular Sciences
|June 19, 2024
PubMed

Abstract:

We launched this Special Issue amidst the COVID-19 pandemic, spurred by the growing interest in nanotherapeutic formulations for delivering SARS-CoV-2 viral messenger Ribonucleic Acid (mRNA) vaccines [...].

More Related Videos

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

8.9K
Manufacture and Drug Delivery Applications of Silk Nanoparticles
09:03

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

15.8K

Related Experiment Videos

Last Updated: Jun 23, 2025

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy
05:06

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy

Published on: November 10, 2023

959
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

8.9K
Manufacture and Drug Delivery Applications of Silk Nanoparticles
09:03

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

15.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K

Articles linked to this work by shared authors, journal, and citation graph.

Implantable medical devices: From basics to state-of-the-art.

Journal of controlled release : official journal of the Controlled Release Society·2026

Immunomodulatory Nanomaterials: Design Strategies, Mechanisms, Biomedical Applications, and Future Perspectives.

Biomedicines·2026

Proteotoxicity and tubular epithelial cell fate in acute kidney injury: Molecular insights and treatment strategies.

Life sciences·2026

Stimulator of Interferon Genes Is a Fine-Tuner, but Not a Prime Mover, of Kidney Inflammation.

The American journal of pathology·2026

Biological Nanocarriers in Cancer Therapy: Cutting Edge Innovations in Precision Drug Delivery.

Biomolecules·2025

Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies.

Physiology (Bethesda, Md.)·2024

Correction: Ormiston et al. Estrogen Signaling During Abrupt Involution and Long-Term Metabolic Signature Similar to Estrogen Receptor-Negative Breast Cancer. Int. J. Mol. Sci. 2026, 27, 1951.

International journal of molecular sciences·2026

Correction: Liu et al. CpLEA5, the Late Embryogenesis Abundant Protein Gene from Chimonanthus praecox, Possesses Low Temperature and Osmotic Resistances in Prokaryote and Eukaryotes. Int. J. Mol. Sci. 2015, 16, 26978-26990.

International journal of molecular sciences·2026

Correction: Almeida et al. Diterpenes: Nature's Hidden Gems of Immunomodulation. Int. J. Mol. Sci. 2025, 26, 2250.

International journal of molecular sciences·2026

Correction: Kim et al. The Tumorigenic Role of Circular RNA-MicroRNA Axis in Cancer. Int. J. Mol. Sci. 2023, 24, 3050.

International journal of molecular sciences·2026

Correction: Choi et al. Synergistic Regenerative Strategies: Combining Polydeoxyribonucleotide with Biochemical and Physical Agents. Int. J. Mol. Sci. 2026, 27, 4355.

International journal of molecular sciences·2026

Correction: Quintero-Espinosa et al. LRRK2 Knockout Confers Resistance in HEK-293 Cells to Rotenone-Induced Oxidative Stress, Mitochondrial Damage, and Apoptosis. Int. J. Mol. Sci. 2023, 24, 10474.

International journal of molecular sciences·2026

[Current Status and Challenges in the Regulation of Weight Management Medical Devices].

Zhongguo yi liao qi xie za zhi = Chinese journal of medical instrumentation·2026

Amenamevir Transfer into Breast Milk in Patients with Herpes Simplex Virus Infection: A Brief Report of a Prospective Multicenter Study.

The Journal of dermatology·2026

Performance of large language models as a source of clinical information on bacteriophage therapy.

Npj viruses·2026

Mannose-decorated nanostructured lipid carriers improve the intracellular activity of antitubercular drugs against Mycobacterium tuberculosis.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Poly (Lipoic Acid) Nanoparticles With High Blood-Brain Barrier Permeability and Enhanced Anti-Ferroptotic Activity for Ischemic Stroke Treatment.

Small (Weinheim an der Bergstrasse, Germany)·2026

Low-intensity pulsed ultrasound-mediated nose-to-brain co-delivery of β-blockers and aPD-L1 enhances glioblastoma immunotherapy.

Nature communications·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us